Morphic (MORF)
(Delayed Data from NSDQ)
$55.74 USD
+23.90 (75.06%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $55.80 +0.06 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MORF 55.74 +23.90(75.06%)
Will MORF be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MORF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MORF
What Makes Morphic (MORF) a New Buy Stock
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
MORF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for February 14th
New Strong Buy Stocks for February 14th
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet
Other News for MORF
Morphic Holding, Boeing rise; Paramount, Devon Energy fall, Monday, 7/8/2024
MORF Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Morphic Holding to Eli Lilly
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Morphic to Participate in Jefferies Global Healthcare Conference
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo